Humanigen, Inc.
Records under this name other than the patents Humanigen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 11 patents it holds.
Showing 1 to 6 of 6 · Back to Humanigen, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,139,544 | EPHA3 Directed Car-T Cells for Treatment of Tumors Formerly held In force · High confidence | In force | High confidence | |
| US 10,919,983 | Immunoglobulin variable region cassette exchange Term ended Term ended May 13, 2026 · From the USPTO record | Term ended | Term ended May 13, 2026 | From the USPTO record |
| US 8,664,365 | Antibodies to EphA3 Lapsed on the fee record Ended Mar 4, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 4, 2026 | From the USPTO record |
| US 8,637,016 | EphA3 antibodies for the treatment of solid tumors Lapsed on the fee record Ended Jan 28, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 28, 2026 | From the USPTO record |
| US 7,981,843 | Antibody specificity transfer using minimal essential binding determinants Lapsed on the fee record Ended Jul 19, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 19, 2023 | From the USPTO record |
| US 7,544,477 | Circularly permutated, interaction-activated proteins Term ended Term ended May 3, 2020 · From the USPTO record | Term ended | Term ended May 3, 2020 | From the USPTO record |